<DOC>
	<DOCNO>NCT00763412</DOCNO>
	<brief_summary>The purpose study provide necessary data experience design large , full scale clinical trial determine certain medicine ( repaglinide ) , increase amount insulin secrete pancreas , improve nutritional status pulmonary function adolescent young adult cystic fibrosis prediabetes improve blood glucose control . The investigator also try determine relationship systemic inflammatory factor glucose impairment .</brief_summary>
	<brief_title>Pilot Feasibility Study Treatment Pre-diabetes Patients With Cystic Fibrosis</brief_title>
	<detailed_description>As people Cystic Fibrosis ( CF ) live well adulthood new complication arise . CF-Related Diabetes ( CFRD ) emerge major complication . Years prior diagnosis CFRD , patient decrease insulin secretion , glucose intolerance , deteriorate pulmonary function , nutritional impairment . There current standard recommendation treatment CF patient prediabetes , little evidence treatment prediabetic state CF patient prevent deterioration lung function , nutritional status potentially slow progression manifest CFRD . To determine feasibility test hypothesis , perform pilot , double-blinded , randomize control trial 20 CF pancreatic insufficient patient age 12 24 year old impair glucose tolerance test ( IGT ) CFRD without fast hyperglycemia ( CFRD-No FH ) assign either placebo Repaglinide 0.5 mg PO 3 - 4 time day meal two year . Patients monitor blood glucose daily follow every 3 month 2 year determine change nutritional status BMI DEXA , lung function test , frequency hospitalization , antibiotic course , degree glucose tolerance , insulin secretion insulin sensitivity . In addition , base evidence increase inflammation type 2 diabetes , correlation systemic inflammatory response different degree glucose tolerance treatment , assessed subject , well another 20 CF pancreatic insufficient match patient normal glucose tolerance study without intervention</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Prediabetic State</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
	<mesh_term>Repaglinide</mesh_term>
	<criteria>Male female 12 24 year old Diagnosis Cystic Fibrosis sweat test exocrine pancreatic insufficiency Must glucose pattern Oral Glucose Tolerance Test fast blood glucose &lt; 126 mg/dl 2 hour : 140 199 mg/dl &gt; 200 mg/dl . Weight must stable within 5 % 3 month prior initiation visit Must able reproducibly perform spirometry base American Thoracic Society guideline Patients receive growth hormone therapy take insulin Patients evidence liver dysfunction Patients statuspost lung liver transplantation Patients receive systemic steroid 28 day 6 month prior study Patients active ABPA steroid Patients take medication affect glucose metabolism contraindicate repaglinide</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>24 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Cystic Fibrosis</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Cystic Fibrosis Related Diabetes</keyword>
	<keyword>Pre-diabetes</keyword>
	<keyword>oral hypoglycemic agent</keyword>
	<keyword>Repaglinide</keyword>
	<keyword>treatment</keyword>
	<keyword>inflammatory marker</keyword>
	<keyword>Lung function</keyword>
	<keyword>nutrition</keyword>
</DOC>